Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.
|Articles|October 1, 2004
Better chronic disease treatment should take center stage
There is a chronic problem with the healthcare system in the United States and no shortage of rhetoric and theory on how to fix it. In the end, it comes down to a matter of focus.
Advertisement
Advertisement
Related to this article
In this discussion, Chad Hatfield, Pharm.D., M.H.A., BCPS, shares his perspective on the evolving role of pharmacy services and the value of collaboration across health care.
CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Five transcranial magnetic stimulation sessions in one day improved processing speed in adults with schizophrenia, which holds promise for future treatment possibilities, according to researcher Heather Burrell Ward, M.D.
Imaging has been associated with four of the five most prevalent low-value services among Medicare beneficiaries.
One of teledentistry's most valuable applications is triage — helping a patient understand whether a concern can wait for an appointment, requires prompt attention or warrants emergency medical care.
Low birth volume fuels rural healthcare obstetric closures, limiting women’s health access—see which hospitals are most at risk.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daiichi Sankyo, Merck withdraw bid for accelerated approval of I-DXd in small cell lung cancer
2
Why consumers still can’t comparison shop for medication
3
Teledentistry is a step in closing the gap in dental care
4
Heather Burrell Ward, M.D., on personalizing TMS in schizophrenia
5